ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY
Retina, 2022 Background/Purpose: Anti–vascular endothelial growth factor therapies have proven effective in treating retinal diseases but come with a high financial burden to the patient and health care system. Biosimilar drugs present an opportunity to decrease the cost of these important ophthalmic medications, and several ophthalmic ...
Kaiser, Peter K. +2 more
openaire +2 more sources
Anti-vascular endothelial growth factor for neovascular glaucoma
Cochrane Database of Systematic Reviews, 2023 Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) medications are specific inhibitors of the primary mediators of neovascularization ...
Rittiphairoj, Thanitsara +2 more
openaire +3 more sources
Intraluminal application of vascular endothelial growth factor enhances healing of microvascular anastomosis in a rat model [PDF]
, 2005 Background: Early reconstitution after injury to the endothelium is an important feature for reducing a number of vessel wall pathologies. We investigated the effect of vascular endothelial growth factor ( VEGF) and its impact on the vascular remodeling ...
Hollenberg, S. M. +8 more
core +2 more sources
Journal of Medical Case Reports, 2021 Background Intravitreal injections of anti-vascular endothelial growth factor are commonly used to treat macular diseases, including diabetic macular edema.
Miwako Yoshimoto +3 more
doaj +1 more source
Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma [PDF]
Journal of Clinical Oncology, 2015 Treatment of glioblastoma (GBM), the most common primary malignant brain tumor in adults, remains a significant unmet need in oncology. Historically, cytotoxic treatments provided little durable benefit, and tumors recurred within several months.
Lu-Emerson, Christine +7 more
openaire +4 more sources
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy [PDF]
Cochrane Database of Systematic Reviews, 2014 Proliferative diabetic retinopathy (PDR) is a complication of diabetic retinopathy that can cause blindness. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision. An alternative treatment such as anti-vascular endothelial growth factor (anti-VEGF), which produces an inhibition of
Martinez-Zapata M. J. +8 more
openaire +7 more sources
Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro [PDF]
, 2001 Angiogenesis, the formation of a new blood supply, is an essential step in tumorigenesis. Although vascular endothelial growth factor (VEGF) is known to be a very potent angiogenic factor in most solid tumors, little is known about its production and ...
Losa, Marco +16 more
core +1 more source
Debate on the various anti-vascular endothelial growth factor drugs
Indian Journal of Ophthalmology, 2008 Khalili Mohammad, Hosseini Hamid
doaj +3 more sources
Anti-vascular endothelial growth factor treatment for eye diseases [PDF]
BMJ, 2012 Treatment is clearly effective but important clinical and public health implications ...
Wong, TY, Cheung, N, Lam, DSC
openaire +4 more sources
Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization
Delhi Journal of Ophthalmology, 2011 Corneal neovascularisation is a potentially blinding condition, an established risk factor for rejection and results in loss of immune privilege. It may occur as a normal physiologic healing response to various stimuli or as an inappropriate local tissue
Srivatsa Sehra, Reetika
doaj +1 more source